MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) is a clinical-stage biotechnology company with a fully-human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. MBVX’s lead antibody is directed at an antigen target expressed on more than 90% of pancreatic cancers and a significant amount of other GI and lung cancers, making the antibody potentially broadly applicable to a wide variety of patients suffering from difficult to treat cancers. The Company has collaborations with Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon, Honor Health and Imaging Endpoints. MabVax has treated 50 patients in Phase I clinical studies with either its therapeutic antibody, MVT-5873, or its PET imaging diagnostic product, MVT-2163, and results of these trials have been presented at leading scientific conferences in June 2017. Additionally, a Phase I clinical study for MBVX’s radioimmunotherapy product designated as MVT-1075 has been authorized to proceed by the FDA and will soon commence with patient enrollment.

MBVX’s unique technology is used to develop therapies based on the human immune response to cancer. Currently, the Company is in Phase I clinical trials for pancreatic cancer, antibody based PET imaging agents and radioimmunotherapy products. Pancreatic cancer therapies are estimated at a $4.2 billion global market by 2025 and radioimmunotherapy global market is expected to reach $7 billion by 2020. MabVax’s current market cap of $14.0 million is far below the average market cap of biotech companies with early stage pancreatic cancer trials. Additionally, Companies involved in phase I clinical trials for pancreatic cancer trials such as Sun Biopharma ($52 million) and Inovio Pharmaceuticals ($563 million) have higher valuations than MabVax. Company’s closest competitor: Nordic Nano Vector with a market cap of $620 million uses radioimmunotherapy for hematologic cancers This leaves potential short-to-mid-term upside for MabVax shares.

  • MBVX is a clinical stage Immuno-Oncology Company developing unique human monoclonal antibody based products to treat cancers
    • Company’s products MVT-5873 and MVT 2163 have demonstrated early safety and potential efficacy signals in phase I clinical trials of monotherapy
    • 32 patients treated in Phase I monotherapy dose escalation safety trial of MVT-5873; Phase Ia results reported at ASCO in June 2017
    • 12 patients treated in Phase I trial of MVT-2163 immunoPET agent. Phase I results reported at SNMMI meeting in June 2017

  • Novel radioimmunotherapy (MVT-1075) product authorized by the FDA for Phase I study
    • Phase I trial initiation anticipated in 2Q17
    • Significant valuations have been afforded to companies in radioimmunotherapy space; Nordic Nano Vector, with a market cap of $620 million, uses radioimmunotherapy for hematological cancers

  • Collaborations with leading cancer research institutions including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon, Honor Health and Imaging Endpoints

More Information | Company Website

 Disclosure

Investor Contact Info:

RedChip Companies Inc.
1017 Maitland Center Commons Blvd.
Maitland, FL 32751
(407) 644-4256
www.RedChip.com

 

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market